Cargando…

1825. Optimizing β-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring

BACKGROUND: Therapeutic drug monitoring (TDM) is a powerful tool to optimize antibiotic exposure. It seldom has been used for β-lactams (BLs). We present our BL data in patients admitted to the surgical intensive care unit (SICU). METHODS: This retrospective study included SICU patients at UF Health...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Shaer, Mohammad H, Rubido, Eric, Lee, Daniel, Klinker, Kenneth, Peloquin, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808752/
http://dx.doi.org/10.1093/ofid/ofz359.087
_version_ 1783461812190052352
author Al-Shaer, Mohammad H
Rubido, Eric
Lee, Daniel
Klinker, Kenneth
Peloquin, Charles
author_facet Al-Shaer, Mohammad H
Rubido, Eric
Lee, Daniel
Klinker, Kenneth
Peloquin, Charles
author_sort Al-Shaer, Mohammad H
collection PubMed
description BACKGROUND: Therapeutic drug monitoring (TDM) is a powerful tool to optimize antibiotic exposure. It seldom has been used for β-lactams (BLs). We present our BL data in patients admitted to the surgical intensive care unit (SICU). METHODS: This retrospective study included SICU patients at UF Health (2016 and 2018) who received BL therapy and had TDM. Data collected included demographics, APACHE scores, platelet count, serum creatinine (Scr), infection source, cultures/susceptibilities, BL regimens, and plasma concentrations. Clinical cure was defined as resolution of infection-related symptoms at the end of therapy. Microbiologic eradication was defined as eradication of causative organism from the primary source out to 30 days after therapy. Pharmacokinetic and statistical analyses were performed on Phoenix v8.0 and JMP Pro v14. RESULTS: A total of 127 patients were included. Table 1 shows the baseline characteristics. The median age was 55 years, and weight was 83 kg. Eighty-three (65%) were male. P. aeruginosa was the most common isolated bacteria (n = 38). Lung was the most common source of infection (n = 50). Table 2 summarizes the median (IQR) doses, infusion times, calculated free trough concentrations (fCmin) of common BLs, and the reported minimum inhibitory concentrations (MICs). Calculated median time above the MIC (fT > MIC) for 66 (52%) patients was 100%. A total of 99 (79%) patients had clinical cure and 67 (61%) patients had microbiologic eradication. For efficacy, the Cmin/MIC ratio predicted the microbiologic eradication in wound infections only (n = 15, OR 1.09 [95% CI 1.01–1.24]). Using stepwise regression, 1-unit increase fT > MIC and APACHE score was associated with 0.84 decrease (P = 0.03) and 0.62 increase (P = 0.004) in days of therapy, respectively. For safety, Figure 2 shows the increase in Scr vs. BL free area under the concentration–time curve from time zero to end of the dosing interval (fAUC(0-tau)). Cefepime fAUC(0-tau) predicted neurotoxicity (OR per 20 unit increase 1.08 [95% CI: 1.01–1.18]). CONCLUSION: In SICU patients, increase in fT > MIC was associated with shorter treatment duration, and fAUC(0-tau) increase was associated with an increase in Scr and incidence of neurotoxicity. TDM is warranted in this population to optimize therapy. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All Authors: No reported Disclosures.
format Online
Article
Text
id pubmed-6808752
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68087522019-10-28 1825. Optimizing β-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring Al-Shaer, Mohammad H Rubido, Eric Lee, Daniel Klinker, Kenneth Peloquin, Charles Open Forum Infect Dis Abstracts BACKGROUND: Therapeutic drug monitoring (TDM) is a powerful tool to optimize antibiotic exposure. It seldom has been used for β-lactams (BLs). We present our BL data in patients admitted to the surgical intensive care unit (SICU). METHODS: This retrospective study included SICU patients at UF Health (2016 and 2018) who received BL therapy and had TDM. Data collected included demographics, APACHE scores, platelet count, serum creatinine (Scr), infection source, cultures/susceptibilities, BL regimens, and plasma concentrations. Clinical cure was defined as resolution of infection-related symptoms at the end of therapy. Microbiologic eradication was defined as eradication of causative organism from the primary source out to 30 days after therapy. Pharmacokinetic and statistical analyses were performed on Phoenix v8.0 and JMP Pro v14. RESULTS: A total of 127 patients were included. Table 1 shows the baseline characteristics. The median age was 55 years, and weight was 83 kg. Eighty-three (65%) were male. P. aeruginosa was the most common isolated bacteria (n = 38). Lung was the most common source of infection (n = 50). Table 2 summarizes the median (IQR) doses, infusion times, calculated free trough concentrations (fCmin) of common BLs, and the reported minimum inhibitory concentrations (MICs). Calculated median time above the MIC (fT > MIC) for 66 (52%) patients was 100%. A total of 99 (79%) patients had clinical cure and 67 (61%) patients had microbiologic eradication. For efficacy, the Cmin/MIC ratio predicted the microbiologic eradication in wound infections only (n = 15, OR 1.09 [95% CI 1.01–1.24]). Using stepwise regression, 1-unit increase fT > MIC and APACHE score was associated with 0.84 decrease (P = 0.03) and 0.62 increase (P = 0.004) in days of therapy, respectively. For safety, Figure 2 shows the increase in Scr vs. BL free area under the concentration–time curve from time zero to end of the dosing interval (fAUC(0-tau)). Cefepime fAUC(0-tau) predicted neurotoxicity (OR per 20 unit increase 1.08 [95% CI: 1.01–1.18]). CONCLUSION: In SICU patients, increase in fT > MIC was associated with shorter treatment duration, and fAUC(0-tau) increase was associated with an increase in Scr and incidence of neurotoxicity. TDM is warranted in this population to optimize therapy. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All Authors: No reported Disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6808752/ http://dx.doi.org/10.1093/ofid/ofz359.087 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Al-Shaer, Mohammad H
Rubido, Eric
Lee, Daniel
Klinker, Kenneth
Peloquin, Charles
1825. Optimizing β-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring
title 1825. Optimizing β-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring
title_full 1825. Optimizing β-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring
title_fullStr 1825. Optimizing β-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring
title_full_unstemmed 1825. Optimizing β-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring
title_short 1825. Optimizing β-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring
title_sort 1825. optimizing β-lactam therapy in surgical intensive care unit patients using therapeutic drug monitoring
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808752/
http://dx.doi.org/10.1093/ofid/ofz359.087
work_keys_str_mv AT alshaermohammadh 1825optimizingblactamtherapyinsurgicalintensivecareunitpatientsusingtherapeuticdrugmonitoring
AT rubidoeric 1825optimizingblactamtherapyinsurgicalintensivecareunitpatientsusingtherapeuticdrugmonitoring
AT leedaniel 1825optimizingblactamtherapyinsurgicalintensivecareunitpatientsusingtherapeuticdrugmonitoring
AT klinkerkenneth 1825optimizingblactamtherapyinsurgicalintensivecareunitpatientsusingtherapeuticdrugmonitoring
AT peloquincharles 1825optimizingblactamtherapyinsurgicalintensivecareunitpatientsusingtherapeuticdrugmonitoring